Transcription factor Foxp1 is essential for the induction of choroidal neovascularization

Meifang Yan, Junjian Li, Li Yan, Xue Li* and Jie-Guang Chen*

Abstract

Background: The exudative form of age-related macular degeneration (AMD) is characterized by abnormal blood vessel growth, which is stimulated by vascular endothelial growth factor (VEGF) released from retinal pigment epithelium (RPE). The angiogenic behaviors of vascular endothelial cells in vitro depend on forkhead box protein P1 (Foxp1), a transcription repressor widely expressed in human and murine tissues during development. In this study, we aimed to determine whether loss of Foxp1 affects laser-induced choroidal neovascularization (CNV) in mouse.

Methods: Eye-selective deletion of Foxp1 was obtained by crossing Foxp1flox/flox with Six3-Cre mice. Laser photocoagulation was delivered to six- to eight-week-old mice to induce CNV. The expression of Foxp1 and Cre was determined by immunofluorescence in cryostat sections of the eyes. Fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and B4 isolectin staining were applied to analyze the leakage, bulge height, and area of CNV lesions, respectively. RPE-choroid tissues were isolated for the determination of VEGF and pigment epithelium derived factor (PEDF) by Western blotting.

Results: Foxp1 was expressed in retinal ganglion cells, RPE, and the choroidal endothelial cells. Laser photocoagulation increased the number of Foxp1+ endothelial cells and induced CNV. Six3-Cre reduced Foxp1 expression in RPE but not the endothelium, leading to a lower level of VEGF in the RPE-choroid. Foxp1 knockout inhibited pathological angiogenesis and vascular leakage of the laser-induced CNV lesions.

Conclusions: Foxp1 regulates the expression of VEGF in the RPE, and inhibition of Foxp1 could potentially be a novel strategy for the prevention and therapy of neovascularization related to AMD.

Keywords: Foxp1, Choroidal neovascularization, Angiogenesis, Laser photocoagulation, Age-related macular degeneration

Background

Age-related macular degeneration (AMD) is a complex, multifactorial disease, and a primary cause of blindness among the elderly. Approximately 10% of AMD patients suffer from the exudative or wet form of AMD that is characterized by choroidal neovascularization (CNV). The newly-formed blood vessels from the choroid invade the retina through fractures in Bruch’s membrane, the extracellular matrix between the choroid and the retinal pigment epithelium (RPE). The immature blood vessels leak fluid below and within the retina, causing edema in...
the eye and central vision loss. The vision-threatening vasculopathy is associated with an abnormal increase of vascular endothelial growth factor (VEGF) [1], a potent pro-angiogenic molecule in the choroid. In animal studies, increased expression of VEGF in the RPE can lead to CNV [2]. Currently, agents that effectively inhibit VEGF become the therapeutic basis for neovascular AMD [3, 4]. However, VEGF helps the maintenance and survival of RPE, and long-term anti-VEGF treatment may have severe side effects and result in geographic atrophy of the ocular tissues [5, 6]. Thus, it remains a challenge to search for new therapeutics based on a better understanding of the genetic mechanisms of neovascular AMD and the molecular regulation of VEGF.

The incidence and progression of AMD increase significantly with age. Multiple conditions accelerate the development of AMD, including dysregulated complement system, oxidative stress, impaired autophagy clearance, and inflammation of endothelial cells [3, 7, 8]. Transcription factor forkhead box protein P1 (Foxp1) is a key regulator of endothelial cell inflammation and plays an important role in heart development [9, 10]. Targeted deletion of Foxp1 in vascular endothelial cells results in increased atherosclerosis in mice by modulating NLRP3 inflammasome activation [11]. In ischemic hindlimb, Foxp1 is highly expressed in endothelial cells at the site of neovascularization. Silencing Foxp1 in vitro results in semaphorin 5B-mediated inhibition of endothelial cell proliferation, migration, and sprouting [12]. These observations show that Foxp1 is essential for angiogenesis in endothelial cells. However, it has not been examined whether this transcription factor regulates the choroidal VEGF, a critical player in CNV.

Foxp1 has been linked to various cognitive disorders. Foxp1-specific deletions, mutations, and chromosomal breakpoints interrupting the gene have been reported in autistic patients with intellectual disabilities and or speech and language deficits [13, 14]. The loss of Foxp1 in autistic patients frequently coincide with ophthalmological abnormalities [15], and autism is unusually common among blind people [13, 16]. As AMD is the primary cause of blindness among the elderly, this study aimed to investigate the roles of Foxp1 in CNV by eye-selective deletion of Foxp1. We crossed Foxp1flox/flox with Six3-Cre mice. Foxp1, but not Six3-Cre, was expressed in choroidal endothelial cells. Six3-Cre was expressed in the RPE cells, and Foxp1 was reduced by the knockout, leading to a lower level of VEGF in the RPE and choroid. Foxp1 knockout (KO) inhibited pathological angiogenesis and vascular leakage of the laser-induced CNV lesion. The results suggest that inhibition of Foxp1 could potentially be a novel strategy for the prevention and therapy of neovascularization related to AMD.

**Methods**

**Animals**

Six- to eight-week-old C57BL/6 J mice (Shanghai Jiesi Laboratory Animal Co., Ltd.), Six3-Cre mice, EGFP-L10a, and Foxp1flox/flox mice (Jackson Lab) used in this study were housed under a 12 h light/dark cycle and given ad libitum access to food and water. All animal experiments were carried out according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The study was approved by the Laboratory Animal Ethics Committee of Wenzhou Medical University (ID Number: xmsq2021-0163). To knockout Foxp1 in the eye, Foxp1flox/flox mice were crossed with the Six3-Cre to generate heterozygous F1 progeny, which was backcrossed with Foxp1flox/flox. The F2 progeny were genotyped by polymerase chain reaction (PCR) according to the protocol provided by Jackson Laboratory, with the following primers: Foxp1flox/flox Forward (5'-TGGTTCACACGAATTTTG-3') and the reverse primer (5'-GGAGTGCTCTCCATCTGA-3'); Six3-Cre Forward (5'-TCGATGCAACGATGAG-3') and the reverse primer (5'-TTCGGCTATACGTAACAGGG-3'). The double deficient KO mice were identified by the presence of Cre and floxed Foxp1 in their tail DNA. The wild-type (WT) littermates, as with the experimental controls, were those that harbor the floxed allele of Foxp1 but without Cre. Mice were euthanized via intraperitoneal injection of pentobarbital (50 mg/kg).

**Laser-induced choroidal neovascularization**

CNV was induced by laser photocoagulation of Bruch’s membrane using the image-guided laser system (Micron IV, Phoenix Research Labs, USA). The mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) diluted in sterile 0.9% saline. The pupils were dilated using compound tropicamide eye drops (Handan Kangye Pharmaceutical Co., Ltd.). Argon laser (Merilas 532α, 532 nm wavelength, 100 mW output energy, 70 ms duration, 50 μm spot size) was used to produce four laser burns in the fundus of each eye. The burning spots were 1–2 papillary diameters away from the optic disc. We considered the occurrence of a vaporizing bubble as evidence of successful laser treatment. The eyes were coated with ofloxacin eye ointment (Shenyang Xingqi Eye Medicine Co., Ltd.) after the laser burn. The mice were put on a heating plate to help their recovery from the experiment. Eyes with excessive laser burns and severe hemorrhage lesions were excluded from the experiments [17].

**Fundus fluorescein angiography (FFA)**

On day six post laser treatment, FFA was used to assess the leakage of CNV. Mice were anesthetized and injected
intraperitoneally with fluorescein sodium solution (2.5% in saline, 0.1 ml). FFA images were taken by Micron IV retinal imaging system at 5 min (early phase) and 10 min (late phase) following the injection. The mean fluorescence intensity (FI) of CNV lesions was calculated using ImageJ (National Institutes of Health, Bethesda, MD) software, and the change was expressed as a percentage of the increase: \[
\left(\frac{FI_{10\text{ min}} - FI_{5\text{ min}}}{FI_{5\text{ min}}} \right) \times 100\%.
\]
CNV leakage was evaluated by scorers blinded to the experimental conditions using the following grading criteria: grade 0 (without leakage): faint or mottled fluorescence; grade 1 (questionable leakage): hyper-fluorescence lesion without a progressive increase in size or intensity; grade 2a (leaky): hyper-fluorescence with an increase in intensity but not in size; grade 2b (pathologically significant leakage): hyper-fluorescence increasing in both intensity and size [18, 19].

**Optical coherence tomography (OCT)**

One day after FFA, when the eyes have recovered from the anesthesia-related opacification of the intraocular lens, a spectral domain optical coherence tomography (SD-OCT) system (Spectralis, Heidelberg Engineering, Heidelberg, Germany) was used for imaging the cross-section of the fundus in real-time. Mice were anesthetized, and the pupils were dilated. The eyes were kept moist using sodium hyaluronate eye drops (Zhejiang Jianfeng Pharmaceutical Co., Ltd.). We chose a deep-enhanced imaging model and B-scan to capture the CNV lesion images. The edges of CNV were traced by ImageJ to help calculate the thickness, defined as the height from the inner border of the RPE to the highest point of the CNV area.

**Preparation and staining of RPE-choroid-sclera complex and retina flat-mounts**

The eyeballs of mice were harvested and fixed in 4% paraformaldehyde (PFA) in phosphate buffered solution (PBS) for 10 min at room temperature. The anterior segment and lens were removed, and the optic nerves were cut off. The neural retina was carefully separated from the RPE-choroid-sclera complex. RPE-choroid-sclera and the retina were post-fixed in PFA for 20 min, washed in PBS, and permeabilized in 0.5% Triton X-100 (in PBS) for 4 h. The tissues were stained for 12 h at room temperature with Alexa Fluor® 594-conjugated GSL I-B4 isolecint (1:300, I21413, Invitrogen), a marker for endothelial cells. To visualize the vascular structures, we flat-mounted RPE-choroid-sclera and the neural retina onto slides in an anti-fade mounting medium (P0126, Beyotime, China). Fluorescent images were captured by a Zeiss LSM 880 microscope.

**FITC-dextran perfusion and melanin bleaching**

Fluorescein Isothiocyanate dextran (FITC-dextran: FD2000S-1G, Sigma) was diluted in distilled water to a concentration of 50 mg/ml. Mice were anesthetized, and 0.2 ml FITC-dextran was injected into the left ventricle of the mouse. Eight minutes later, the mice were sacrificed. Eyeballs were enucleated and fixed in 4% PFA for 1 h at room temperature. After washing in PBS, the eyeballs were incubated with 2% hydrogen peroxide (H₂O₂) for 15 min at room temperature and then 10% H₂O₂ at 55 °C for 2.5 h to bleach the pigment [20]. The eyeballs were washed in PBS, and the anterior segment and lens were removed. The RPE-choroid-sclera complex and the neural retina were prepared and mounted on glass slides. Fluorescent images were captured by a Zeiss LSM 880 microscope.

**Immunofluorescence**

To determine the expression of Foxp1 and cell marker proteins, we prepared frozen sections of the eyeballs. Eyeballs were first fixed in 4% PFA for 0.5 h, another 1.5 h after poking a hole in the cornea and dehydrated in 30% sucrose. The anterior segment was cut off, and the remaining were frozen in OCT compound (Sakura Tissue Tek, Torrance, CA) and sectioned with a cryostat (HM505E, Microm, Germany) at 10 μm. The cryosections were permeabilized and blocked in PBS containing 0.3% Triton X-100, 1% BSA, and 5% donkey serum for 2 h at room temperature. After overnight incubation at 4 °C with primary antibodies, the sections were washed with PBS, incubated with secondary antibodies for 2 h, and mounted on glass slides in Slowfade Gold medium (Invitrogen) that contains DAPI for nuclear staining. The primary antibodies used in this study were anti-CD31 antibody (1:300, ab7388, Abcam), anti-FOXPI antibody (1:100, ab227649, Abcam), anti-CRE antibody (1:300, Sigma, MAB3120), anti-VEGF antibody (1:50, MA5-13182, Invitrogen), anti-pigment epithelium derived factor (PEDF) antibody (1:100, ab180711, Abcam) and anti-OTX2 antibody (1:300, AF1979, R&D Systems). In control experiments, the primary antibodies were replaced by PBS. The secondary antibodies from Jackson ImmunoResearch Laboratories include Cy3-conjugated anti-Rabbit (1:400), Alexa Fluor™488 anti-Rat IgG, Alexa Fluor™488 anti-Mouse IgG, Alexa Fluor™488 anti-Goat IgG, Alexa Fluor™647 anti-Rat IgG, Alexa Fluor™647 anti-Mouse IgG, and Alexa Fluor™647 anti-Goat IgG. Immunofluorescence images were captured using a confocal microscope (Zeiss LSM 880).

For detection of Cre recombinase activity, Six3-Cre transgenic mice were crossed with the EGFP-L10a reporter strain (Jackson Lab). The reporter allows
the fusion protein of EGFP and ribosomal L10a to be expressed in specific cell populations in response to the presence of Cre recombinase, which removes a loxp-flanked stop cassette placed between the promoter and the fusion gene [21]. The eyeballs from the adult progenies were harvested, and the cryostat sections were prepared as above. EGFP after the Cre mediated recombination was detected by a fluorescence microscope.

Western blot analysis
RPE-choroid tissues were isolated from Foxp1 KO and the control littermates following an established protocol [22]. Briefly, the anterior segment and neural retina were removed from the eyes. The RPE-choroid was separated from the sclera and lysed in ice-cold RIPA buffer (P0013B, Beyotime Biotech, China) containing a cocktail of protease inhibitors (5871S, Cell Signaling Technologies, USA). The protein concentration in isolation was measured by BCA Protein Assay Kit (P0010, Beyotime, China). The samples were loaded onto sodium dodecyl sulfate–polyacrylamide gels, separated by electrophoresis, transferred to polyvinylidene fluoride membranes (Merck Millipore). The membrane was blocked in TBS-T (150 mM NaCl, 10 mM TRIS–HCl pH 7.5, and 0.1% Tween 20) containing 5% (w/v) dry milk and probed separately with Mouse anti-VEGF-A (1:200, ab1316, Abcam), Rabbit anti-PEDF (1:2000, ab180711, Abcam) and Mouse anti-α-tubulin (1:4000, ab52866, Abcam) antibodies. The signals were detected with secondary antibodies and quantified using Odyssey infrared laser imaging system (LI-COR Biosciences).

Statistical analysis
For all the measurements in this study, data were presented as mean ± standard deviation (SD) from 3 to 5 mice in each group. The student’s t-test was used for the comparison between two groups. As for multiple comparisons, one-way ANOVA was performed, followed by Tukey’s post-hoc multiple comparison test. * P<0.05 was considered as statistically significant.
Results
Foxp1 is expressed in RGC, RPE and choroidal endothelial cells
Foxp1 is widely expressed in human and murine tissues. FOXP1 mRNA and protein are found in the lymph node, lungs, brain, kidneys, endocrine organs, and reproductive systems [15]. In the mouse brain, Foxp1 is expressed in the projection neurons of the neocortex and the CA1/CA2 hippocampal subfields [23, 24]. In the neural retina, Foxp1 is partially colocalized with Foxp2 in retinal ganglion cells (F-RGcs) [25]. To delineate the overall pattern of Foxp1 expression in the mouse eye, we performed immunofluorescence staining of Foxp1 on cryostat-sectioned eyeballs. Foxp1 staining was found in the ganglion cell layer, as expected for F-RGCs. Irregular spots of Foxp1 were also noticed in the choroid where they colocalized with CD31-positive endothelial cells (Fig. 1a). It is possible that Foxp1 participates in the formation and maintenance of the choroidal vascular bed. Interestingly, Foxp1 was present in the RPE layer and colocalized with OTX2, a marker for RPE cells (Fig. 1b). RPE cells have been shown to produce VEGF and initiate the process that leads to pathologic neovascularization in AMD [26, 27].

To study whether Foxp1 is involved in the neovascular AMD, we generated CNV in vivo model by laser-induced photoocoagulation, a procedure relying on laser injury to perforate Bruch’s membrane. The destruction led to the growth of new blood vessels from the choroid into the subretinal space, which recapitulates the main features of the exudative form of human AMD [28]. CNV was induced in age-matched C57BL/6 mice that were randomly assigned to control and laser-treatment groups (6 to 8 weeks old). The CNV lesions, imaged by optical coherence tomography [29], exhibited a spindle-shaped hyper-reflective area in the subretinal space (Fig. 2a). The histopathological progression of angiogenesis can be arbitrarily divided into two phases, injury/angiogenesis (days 1 to 6 post-laser) and the mature/repairing phase (after day 7) [30]. Maximum CNV was observed around day 7 after the laser burn, followed by slow regression or tissue repairing that led to the reduction of the CNV

| Results | Foxp1 is expressed in RGC, RPE and choroidal endothelial cells |
|---------|----------------------------------------------------------------|
| Foxp1 is widely expressed in human and murine tissues. FOXP1 mRNA and protein are found in the lymph node, lungs, brain, kidneys, endocrine organs, and reproductive systems [15]. In the mouse brain, Foxp1 is expressed in the projection neurons of the neocortex and the CA1/CA2 hippocampal subfields [23, 24]. In the neural retina, Foxp1 is partially colocalized with Foxp2 in retinal ganglion cells (F-RGCs) [25]. To delineate the overall pattern of Foxp1 expression in the mouse eye, we performed immunofluorescence staining of Foxp1 on cryostat-sectioned eyeballs. Foxp1 staining was found in the ganglion cell layer, as expected for F-RGCs. Irregular spots of Foxp1 were also noticed in the choroid where they colocalized with CD31-positive endothelial cells (Fig. 1a). It is possible that Foxp1 participates in the formation and maintenance of the choroidal vascular bed. Interestingly, Foxp1 was present in the RPE layer and colocalized with OTX2, a marker for RPE cells (Fig. 1b). RPE cells have been shown to produce VEGF and initiate the process that leads to pathologic neovascularization in AMD [26, 27]. To study whether Foxp1 is involved in the neovascular AMD, we generated CNV in vivo model by laser-induced photoocoagulation, a procedure relying on laser injury to perforate Bruch’s membrane. The destruction led to the growth of new blood vessels from the choroid into the subretinal space, which recapitulates the main features of the exudative form of human AMD [28]. CNV was induced in age-matched C57BL/6 mice that were randomly assigned to control and laser-treatment groups (6 to 8 weeks old). The CNV lesions, imaged by optical coherence tomography [29], exhibited a spindle-shaped hyper-reflective area in the subretinal space (Fig. 2a). The histopathological progression of angiogenesis can be arbitrarily divided into two phases, injury/angiogenesis (days 1 to 6 post-laser) and the mature/repairing phase (after day 7) [30]. Maximum CNV was observed around day 7 after the laser burn, followed by slow regression or tissue repairing that led to the reduction of the CNV |

### Fig. 2
Choroidal neovascularization (CNV) is accompanied by increased Foxp1 expression. 

- **a** Representative spectral domain optical coherence tomography (SD-OCT) B-scan images at the indicated times following laser treatment. Arrows point to the location of CNV in the choroid. Scale bar = 50 μm. 
- **b** CNV thickness was calculated from the SD-OCT images. 
- **c** Cryostat sections from the eyes burned by the laser were immunostained at day 7 with the antibodies against CD31 (white) and Foxp1 (red). Scale bar = 100 μm. 
- **d** Magnified images of the square box in (c). Arrows depict the colocalization of Foxp1 and the endothelial marker CD31. Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. 

**GCL**, ganglion cell layer; **INL**, inner nuclear layer; **ONL**, outer nuclear layer; **CH**, choroid; **SC**, sclera. 

| p-value | n = 3 in each group. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test |

---

| CNV Time Course | Control | CNV 12h | CNV 24h |
|-----------------|---------|---------|---------|
| CNV 2d | CNV 7d | CNV 14d | CNV 21d |
| CNV 28d | CNV 35d |

| CNV Thickness SD-OCT (μm) | Control | CNV 7d | CNV 14d | CNV 21d |
|---------------------------|---------|---------|---------|---------|
| CNV 28d | CNV 35d | | | |
thickness (Fig. 2b). The maximal CNV on day 7 enclosed many CD31-positive endothelial cells. Foxp1 was also present in the endothelial cells of the CNV (Fig. 2c–d). As Foxp1 in vitro promotes endothelial cell proliferation, migration, and sprouting [12], an inhibition of Foxp1 in the choroidal endothelium could suppress the development of CNV.

**Six3-Cre deletes Foxp1 in the RPE, but not endothelial cells.**

To assess Foxp1 contribution to the CNV, we generated Foxp1 double deficient mice by crossing Foxp1fl/fox with the Six3-Cre mice. Six3-Cre mice express nuclear-localized Cre recombinase under the control of the murine Six3 promoter, a transcription factor expressed in the retina and the ventral aspect of the eye [31]. The knockout progenies were identified by the expression of floxed Foxp1 (300 bp) and Cre enzyme (405 bp) (Fig. 3a). To determine where precisely the Cre was expressed in the eye, we crossed the Six3-Cre with a reporter mouse strain, EGFP-L10a. Expression of the Cre enzyme drove the removal of a lox-flanked stop cassette placed between the promoter and the fusion protein of EGFP and ribosomal L10a [21], and thus marked the site of recombination by EGFP. The reporter EGFP was found to be expressed in the GCL (Ganglion cell layer) and INL (Inner nuclear layer) of the retina. Unexpectedly, we found that the RPE was also labeled by fluorescence. However, no EGFP signal was detected underneath the RPE, suggesting that Cre recombination occurred in the RPE but not in choroidal endothelial cells (Fig. 3b).

To confirm the Cre expression and the knockout of Foxp1 in RPE cells, we examined the expression of Foxp1 and Cre by immunofluorescence. No immunostaining was present in the control sections that eliminated the first antibody. Foxp1 was detected in the RPE of the progeny that did not express Six3-Cre. In the KO mice with Cre expression, Foxp1 staining was weakened (Fig. 3c–d), indicating that Cre-mediated recombination in the RPE caused excision of the floxed Foxp1.
RPE maintains the choriocapillaris (CC) in the normal eye and participates in the pathogenesis of CNV in AMD [32]. RPE-related changes have been found in patients with neovascular age-related macular degeneration [33]. Alterations in RPE-secreted factors are sufficient to cause vascular changes and CNV in an iPSC-RPE-CC model [34]. VEGF is produced by the RPE cells and acts as paracrine signaling between RPE and CC [35]. Blocking VEGF signaling pathway inhibits ocular neovascularization [36]. On the contrary, over-expression of VEGF in the RPE can lead to CNV [2]. All these studies demonstrate that secretion of VEGF from the RPE is a critical determinant for CNV. Therefore, we quantified the expression levels of VEGF-A and PEDF from the isolated
RPE-choroid tissue by Western blotting. VEGF-A, but not PEDF, was significantly reduced in Foxp1 KO mice (Fig. 4a–c). Consistently, VEGF immunostaining was weaker in the KO mice than in the control (Fig. 4d–e), suggesting that VEGF is under Foxp1’s regulation in the RPE.

**Foxp1 knockout inhibits laser-induced CNV but does not affect the normal vasculature**

To study the roles of Foxp1 in CNV, we performed laser-induced CNV in control and KO mice. The procedure generated four laser spots per eye centered around the optic disc. Heat coagulation by laser led to inflammation of the choroidal tissue. We examined the inflammation-induced vascular leakage with FFA on day 6. The mice were injected with fluorescein sodium intraperitoneally, and the fluorescence was examined at 5 and 10 min after the injection. Hyper-fluorescence appeared in the laser spots of the wild-type (WT) mice at 5 and 10 min, indicating a high permeability and reduced clearance of fluorescein in the newly formed choroidal vessels. In contrast, the fluorescence from the laser-induced CNV in the KO mice was lower, and the percentage of the increase in FI from 5 to 10 min was reduced by the KO of Foxp1 (WT, 90% vs. Foxp1 KO, 68%; Fig. 5a–b). By leakage grading, the CNV lesion with pathologically significant leakage (grade 2b) was reduced in KO mice (Fig. 5c). After recovery from the anesthesia-related lens opacification in FFA, fundus images were captured by SD-OCT on day 7 (post laser injury). The thickness of CNV as measured by OCT scanning decreased from 45.2 to 30.6 μm by Foxp1 KO (Fig. 6a–b). We next analyzed neovessel formation by lectin staining. The eyes were harvested and stripped of the retina. RPE-choroid-sclera flat-mounts
were prepared and stained with Alexa Fluor® 594-conjugated GSL I-B4 isolectin. The isolectin-positive area of laser-induced CNV spots in the control was 14386 μm², whereas the average spot in Foxp1 KO mice was 9445 μm² (Fig. 6c), demonstrating that neovascularization was reduced. Together, the data shows that the knockout of Foxp1 dampens vascular leakage and inhibits pathological angiogenesis of CNV in mice.

VEGF serves a trophic role for choroidal vessels that nourish the outer retinal layers. To determine whether reduced VEGF in Foxp1 KO mice had a profound effect on the vascular bed, we visualized the microvascularity in the choroid and retina. Control and Foxp1 KO mice were injected with FITC-dextran [37]. The neural retina and RPE-choroid-sclera complex from the pigment-bleached eyeballs were flat-mounted and examined by fluorescent microscopy. We did not find any shrunken area or aberrant fluorescent accumulations in the choroid (Fig. 7a–b), suggesting that there was no atrophy or leakage of the choroidal capillaries in the KO mice. Though the KO partially reduced VEGF, the choriocapillaris may only require a base level of VEGF for maintenance. In addition, the central retinal vasculature supplies oxygen and nutrients to the inner retinal layers. Retinal microvascular bed in the KO mice was as normal as that of control; abnormalities such as aneurysm and tuft of neovascular vessels were not detected in the deep plexus layer of the retinal capillary (Fig. 7c–d). These results suggest that Foxp1 in the RPE and retina may not be essential for maintaining blood vessels in the eyes of adult mice.

**Discussion**

In this study, we found that knockout of Foxp1 reduces laser-induced CNV in mice. The Six3-Cre did not remove Foxp1 in the choroidal endothelial cells but excised the
gene in the retina and RPE, resulting in reduced VEGF in the RPE and choroid and partial reduction of CNV. Since endothelial cell proliferation, migration, and sprouting in vitro depend on Foxp1 [12], blocking Foxp1 in the endothelial cells would also inhibit the growth of new blood vessels. Thus, inhibition of Foxp1 may potentially be a novel strategy for preventing and treating wet AMD. Molecular strategies such as siRNA or CRISPR are available to knockdown or knockout Foxp1 in vivo [24].

Homozygous deletion of Foxp1 is embryonically lethal due to a cardiac defect [38]. Therefore, we took an eye-specific deletion of Foxp1 by crossing Foxp1^fl/fl^ with Six3-Cre mice. The Six3-Cre mice have been used to knock out genes in non-vascular tissues of the eye. It was reported that the Cre is not expressed in endothelial cells and the RPE in developing eyes of E14.5-P5 mice [39, 40]. By crossing with a Cre reporter strain of mice, we confirmed that Six3-Cre was not expressed in the choroidal endothelium. However, we discovered a robust expression of the EGFP reporter in the RPE of adult mice (Fig. 3b), revealing the location of Cre-mediated recombination in the RPE. Considering the aforementioned studies, we speculate that the Six3-Cre may be expressed only in the adult but not developing RPE. A regionally and temporally restricted expression of Cre in the adult RPE would provide a valuable tool for the study of AMD.

RPE produces and secretes soluble VEGF isoforms toward the basolateral side, while the CC preferentially expresses its receptors on the side facing the RPE. The soluble VEGF diffuses across Bruch’s membrane to reach the CC [41], and thus maintains the CC. Abnormal secretion of VEGF promotes the pathogenesis of choroidal neovascularization in AMD [32]. RPE increases the VEGF secretion during the development of AMD upon noxious stimulations, which include hypoxia, oxidative stress, hyperglycemia, and cytokines [42]. It is unclear how VEGF may be regulated by the loss of Foxp1 in RPE cells. However, in murine bone marrow-derived dendritic cells, silencing Foxp1 inhibits the production and secretion of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Conversely, overexpression of Foxp1 increases cytokine production [43]. Knockout of Foxp1 in RPE might repress the cytokines, thereby reducing the stimulation for the production or secretion of VEGF in response to the laser-photoradiation.

RPE is also one of the sources that provide VEGF during the development of diabetic retinopathy [44]. Diabetic retinopathy is a common complication of diabetes mellitus that causes retinal neovascularization, and in the late-stage of the disease, results in macular edema and vision loss. VEGF is a compelling therapeutic target for diabetic retinopathy [45]. We do not know whether VEGF in other retinal cells may be regulated by Foxp1 as well. Nevertheless, the protective physiological and vision-threatening pathological functions played by VEGF render the regulation of VEGF a highly interesting topic for future exploration.
Conclusions
We showed that transcription factor Foxp1 is expressed in RGC, RPE, and the choroidal endothelial cells of mice. Six3-Cre-mediated recombination of Foxp1^flox/flox knockouts the Foxp1 in RPE, leading to reduced VEGF in RPE-choriocapillaris tissue. The knockout of Foxp1 inhibits laser-induced CNV in mice. The results suggest that Foxp1 may be essential for the induction of CNV. Foxp1 could potentially be a novel target for prevention of and therapy for neovascularization related to exudative AMD.

Acknowledgements
Not applicable.

Authors’ contributions
JGC designed the research. MY, JL, LY, and XL performed the experiments. MY analyzed the data. JGC and XL drafted the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data generated or analyzed during this study are included in this text.

Declarations

Ethics approval and consent to participate
All animal experiments were carried out according to the AVRO Statement for the Use of Animals in Ophthalmic and Vision Research. The study was approved by the Laboratory Animal Ethics Committee of Wenzhou Medical University (ID Number: xmsq2021-0163).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, State Key Laboratory of Optometry, Ophthalmology and Vision Science, and Zhejiang Provincial Key Laboratory of Optophthalmology and Ophthalmology, 270 Xueyuan Road, Wenzhou, Zhejiang 325027, People’s Republic of China. 2 Joint Shantou International Eye Center (JSIEC) of Shantou University and the Chinese University of Hong Kong, Shantou, Guangdong 515000, People’s Republic of China.

Received: 17 August 2021 Accepted: 13 February 2022 Published online: 06 March 2022

References
1. Kawak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158–64.
2. Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS One. 2011;6(7):e21768.
3. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124(4):1430–8.
4. Ferrara N, Adams AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.
5. Ford KM, Saint-Geniez M, Walshe T, Zahr A, D’Amore PA. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2011;52(15):9478–87.
6. Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31.
7. Klettner A, Kauppinen A, Blasiak J, Roeder J, Salminen A, Kaarniranta K. Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization. Int J Biochem Cell Biol. 2013;45(7):1457–67.
8. Miller JW, Bagheri S, Vavvas DG. Advances in age-related macular degeneration understanding and therapy. US Ophthalmic Rev. 2017;10(2):119–30.
9. Kanter JE. FOXP1: a gatekeeper of endothelial cell inflammation. Circ Res. 2019;125(6):606–8.
10. Li H, Wang Y, Liu J, Chen X, Duan Y, Wang X, et al. Endothelial Klf2-Foxp1-TGFbeta signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics. 2021;11(4):1609–25.
11. Zhuang T, Liu J, Chen X, Zhang L, Pi J, Sun H, et al. Endothelial Foxp1 suppresses atherosclerosis via modulation of MRP3 inflammasome activation. Circ Res. 2019;125(6):590–605.
12. Grundmann S, Lindmayer C, Hans FP, Hoefer I, Heibing T, Pasterkamp G, et al. FoxP1 stimulates angiogenesis by repressing the inhibitory guidance protein semaphorin SB in endothelial cells. PLoS One. 2013;8(9):e70873.
13. Hamdan FF, Daoud H, Rochefort D, Piton A, Gauthier J, Langlois M, et al. De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am J Hum Genet. 2010;87(5):671–8.
14. Le Fevre AK, Taylor S, Malek NH, Horn D, Cann CW, Abdul-Rahman OA, et al. FOXP1 mutations cause intellectual disability and a recognizable phenotype. Am J Med Genet A. 2013;161A(12):3166–75.
15. Meerschaert I, Rochefort D, Revençu N, Pêtre J, Corsello C, Rouleau GA, et al. FOXP1-related intellectual disability syndrome: a recognisable entity. J Med Genet. 2017;54(9):613–23.
16. Solliå E, Graham SA, Vino A, Froehlich H, Vreeburg M, Dimitopoulou D, et al. Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder. Hum Mol Genet. 2016;25(3):546–57.
17. Gong Y, Li J, Sun Y, Fu Z, Liu Q, Evans L, et al. Optimization of an image-guided laser-induced choroidal neovascularization model in mice. PLoS One. 2015;10(7):e0132643.
18. Yu HG, Liu X, Kiss S, Connolly E, Gragoudas ES, Michaud NA, et al. Increased choroidal neovascularization following laser induction in mice lacking lysyl oxidase-like 1. Invest Ophthalmol Vis Sci. 2008;49(6):2599–605.
19. Marmeros AG, She H, Zambarkaj H, Hashizume H, Connolly EJ, Kim I, et al. Endogenous endostatin inhibits choroidal neovascularization. FASEB J. 2007;21(14):3809–18.
20. Kim SY, Assavachananont J. A new method to visualize the intact subretinal from retinal pigment epithelium to retinal tissue in whole mount of pigmented mouse eyes. Transl Vis Sci Technol. 2016;5(1):6.
21. Dougherty JD. The expanding toolkit of translating ribosome affinity purification. J Neurosci. 2017;37(50):12079–87.
22. Ida H, Boylan SA, Weigal AL, Smit-McBride Z, Chao A, Gao J, et al. EST analysis of mouse retina and RPE/choroid cDNA libraries. Mol Vis. 2004;10:439–44.
23. Araujo DJ, Toriumi K, Escamilla CO, Kulkarni A, Anderson AG, Harper M, et al. Foxp1 in forebrain pyramidal neurons controls gene expression required for spatial learning and synaptic plasticity. J Neurosci. 2017;37(45):10917–31.
24. Li X, Xiao J, Frohlich H, Tu X, Li L, Xu Y, et al. Foxp1 regulates cortical radial migration and neuronal morphogenesis in developing cerebral cortex. PLoS One. 2015;10(5):e0127671.
25. Roussos DL, Qiao M, Kagan RD, Yamagata M, Palmer RB, Sanes JR. Two pairs of on and off retinal ganglion cells are defined by intersectional patterns of transcription factor expression. Cell Rep. 2016;15(9):1930–44.
26. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119–26.
27. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular...
endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):853–68.
28. Shahi RS, Soetikno BT, Lajko M, Fawzi AA. A mouse model for laser-induced choroidal neovascularization. J Vis Exp. 2015;106:e53502.
29. Wigg JP, Zhang H, Yang D. A quantitative and standardized method for the evaluation of choroidal neovascularization using Micron III fluorescein angiograms in rats. PloS One. 2015;10(5):e0128418.
30. Parsons N, Annamalai B, Obert E, Schnabl G, Tomlinson S, Rohrer B. Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization. Mol Immunol. 2019;108:8–12.
31. Furuta Y, Lagutin O, Hogan BL, Oliver GC. Retina- and ventral forebrain-specific Cre recombinase activity in transgenic mice. Genesis. 2000;26(2):130–2.
32. Miller H, Miller B, Ryan SJ. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci. 1996;27(11):1644–52.
33. Roberts PK, Baumann B, Schlantiz FG, Sacu B, Bolz M, Pircher M, et al. Retinal pigment epithelial features indicative of neovascular progression in age-related macular degeneration. Br J Ophthalmol. 2017;101(10):1361–6.
34. Farnoodian M, Kinter JB, Yadraniji Aghdami S, Zaitoun I, Sorenson CM, Sheibani N. Expression of pigment epithelium-derived factor and thrombospondin-1 regulate proliferation and migration of retinal pigment epithelial cells. Physiol Rep. 2015;3(1):e12266.
35. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol. 1997;235(5):313–9.
36. Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376–9.
37. Miyata S, Morita S. A new method for visualization of endothelial cells and extravascular leakage in adult mouse brain using fluorescein isothiocyanate. J Neurosci Methods. 2011;202(1):9–16.
38. Wang B, Weidenfeld J, Lu MM, Maika S, Kuze WA, Morrisey EE, et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development. 2004;131(18):4477–87.
39. Zhang J, Fuhrmann S, Vetter ML. A nonautonomous role for retinal frizzled-5 in regulating hyaloid vitreous vasculature development. Invest Ophthalmol Vis Sci. 2008;49(12):5561–7.
40. Wei Y, Gong J, Thimmulappa RK, Kosmider B, Biswal S, Duh EJ. Nf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching. Proc Natl Acad Sci U S A. 2013;110(41):E3910–8.
41. Saint-Geniez M, Maldonado AE, D’Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47(7):3135–42.
42. Klettner A, Roeder J. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differentially regulated by different Mitogen-activated protein kinases. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):1487–92.
43. Guo Z, Tao Y, Yin S, Song Y, Lu X, Li X, et al. The transcription factor Foxp1 regulates the differentiation and function of dendritic cells. Mech Dev. 2019;158:103554.
44. Bucolo C, Barbieri A, Viganò I, Marchesi N, Bandello F, Drago F, et al. Short- and long-term expression of VEGF: a temporal regulation of a key factor in diabetic retinopathy. Front Pharmacol. 2021;12:707909.
45. Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018;7:212532.